SCHEMBL1076503

SCHEMBL1076503

Cn1ccc(I)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21720194 0.65
SCHEMBL3034539 0.65
SCHEMBL13453304 0.65
SCHEMBL3077937 0.65
SCHEMBL652873 0.65
SCHEMBL570057 0.65
SCHEMBL3078481 0.65
SCHEMBL3077935 0.65
SCHEMBL1662883 0.65
SCHEMBL811677 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503457-B2 Fluorine-containing pyrimidine compound, and method for producing same UNIMATEC CO., LTD. (JP) 2025-12-23 US disclosed
WO-2024222899-A1 MEMBRANE-ASSOCIATED TYROSINE AND THREONINE KINASE INHIBITOR AND USE THEREOF 海南先声再明医药股份有限公司 2024-10-31 WO disclosed
CN-118525018-A Bialkyne compound and application thereof 上海艾力斯医药科技股份有限公司 2024-08-20 CN disclosed
WO-2024091473-A1 TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS REVERE PHARMACEUTICALS (US) 2024-05-02 WO disclosed
CN-117377668-A Inhalant formulations of PGDH inhibitors and methods of use thereof 迈欧伏特治疗公司 2024-01-09 CN disclosed
CN-112088157-B Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors 拉文纳制药公司 2023-12-26 CN disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 US disclosed
US-20230340011-A1 STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS Asteroid Therapeutics 2023-10-26 US disclosed
CN-116601158-A Modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2023-08-15 CN disclosed
WO-2023116779-A1 DIALKYNE COMPOUND AND USE THEREOF 上海艾力斯医药科技股份有限公司 2023-06-29 WO disclosed
US-9812653-B2 Carbazole compound and organic light-emitting device including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-11-07 US disclosed
US-20170305953-A1 14-MEMBERED KETOLIDES AND METHODS OF THEIR PREPARATION AND USE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-10-26 US disclosed
CN-105073747-B Heterocyclic compounds and their use 普莱希科公司 2017-06-06 CN disclosed
EP-2739614-B1 AMINOCHROMANEs, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBVIE DEUTSCHLAND (DE) 2017-02-22 EP disclosed
EP-3087155-A1 CONTROL OF SUSTAINED CASING PRESSURE IN WELLBORE ANNULI Albemarle Corporation (US) 2016-11-02 EP disclosed
US-20160289527-A1 CONTROL OF SUSTAINED CASING PRESSURE IN WELLBORE ANNULI ALBEMARLE CORP (US) 2016-10-06 US disclosed
WO-2015100004-A1 CONTROL OF SUSTAINED CASING PRESSURE IN WELLBORE ANNULI ALBEMARLE CORPORATION (US) 2015-07-02 WO disclosed
WO-2015089337-A1 BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY BIOGEN IDEC MA INC. (US) 2015-06-18 WO disclosed
EP-2454257-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES Abbott Laboratories (US) 2012-05-23 EP disclosed
WO-2011008915-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 WO disclosed